Invention Grant
- Patent Title: Oligonucleotide sequences targeting transcription factor TSC22D4 for the treatment of insulin resistance
-
Application No.: US16862930Application Date: 2020-04-30
-
Publication No.: US11053499B2Publication Date: 2021-07-06
- Inventor: Stephan Herzig , Mauricio Berriel Diaz , Tobias Schafmeier
- Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
- Applicant Address: DE Heidelberg
- Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
- Current Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
- Current Assignee Address: DE Heidelberg
- Agency: Saliwanchik, Lloyd & Eisenschenk
- Priority: EP15160259 20150323
- Main IPC: C12N15/113
- IPC: C12N15/113 ; C12Q1/68
Abstract:
The present invention relates to oligonucleotide inhibitors of the TSC22D4 activity or expression and their uses for the prevention, treatment, and/or regulation of insulin resistance, metabolic syndrome and/or diabetes and/or for improving insulin sensitivity in a mammal.
Public/Granted literature
- US20200255834A1 OLIGONUCLEOTIDE SEQUENCES TARGETING TRANSCRIPTION FACTOR TSC22D4 FOR THE TREATMENT OF INSULIN RESISTANCE Public/Granted day:2020-08-13
Information query
IPC分类:
